Eric T. Schneiderman has begun an inquiry into whether Turing Pharmaceuticals violated antitrust rules by restricting distribution of a drug, Daraprim, as a way to thwart generic competition.
New York Attorney General Examining Whether Turing Restricted Drug Access
